Previous 10 | Next 10 |
DUBLIN, Ireland, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that the oral and intravenous (IV) formu...
Nabriva Therapeutics (NASDAQ: NBRV ) has earned a $5M milestone payment under its licensing agreement with Sinovant Sciences related to the U.S. regulatory approval of Xenlata (lefamulin). More news on: Nabriva Therapeutics plc, Healthcare stocks news, Read more ...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Nabriva ha...
DUBLIN, Ireland, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will present data at the ASM/ESC...
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Chief Execu...
Nabriva Therapeutics plc (NASDAQ: NBRV ) +23% . More news on: Nabriva Therapeutics plc, VIVUS, Inc., Seadrill Limited, Stocks on the move, Read more ...
August 20, 2019 Palm Beach, FL –August 20, 2019 – Cancer drug market revenues have been steadily rising in the past few years and all indicators predict that they will continue to rise over the next several years. According to industry sources, in 20118 oncology ...
Gainers: NBRV +20.3% . VNET +13.2% . BIDU +9.1% . YUMA +9.0%. MRNA +7.4% . More news on: Nabriva Therapeutics plc, 21Vianet Group, Inc., Baidu, Inc., Stocks on the move, , News on ETFs Read more ...
First New IV and Oral Antibiotic with a Novel Mechanism of Action Approved in Nearly Two Decades Provides Critically Needed Treatment Option for Adult Patients with CABP XENLETA Expected to be Available mid-September 2019 Conference call and webcast today at 4:30 p.m. ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
News, Short Squeeze, Breakout and More Instantly...
Nabriva Therapeutics plc Company Name:
NBRV Stock Symbol:
NASDAQ Market:
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment ...
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Na...
- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, ...